Giuseppe Di Grazia

Dr. Giuseppe Di Grazia

Department of Human Pathology "G. Barresi", University of Messina, Messina, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Giuseppe Di GraziaGiuseppe Di Grazia
Giuseppe Di Grazia
ADArianna Dri
Arianna Dri
AGAngela Grieco
Angela Grieco
CMClaudia Martinelli
Claudia Martinelli
MPMichela Palelschi
Michela Palelschi
MGMario Giuliano
Mario Giuliano
Background: Hormone-receptor-positive (HR+)/HER2-negative (HER2−) breast cancer (BC) is characterized by low immunogenicity and an immunosuppressive microenvironment. These features likely contribute to the inconsistent clinical activity of immune checkpoint inhibitors (ICIs) in this BC subtype. We conducted a systematic review of clinical trials evaluating ICIs in HR+/HER2− BC patients, focusing on potential biomarkers of response and resistance to these drugs. Methods: We systematically searched in Medline via PubMed, EMBASE, and CENTRAL for phase II/III clinical trials published between 2013 and 2023, testing ICIs alone or in combination with other agents in HR+/HER2− BC patients at any stage. All the searches were performed up to 27 January 2024. Data on study characteristics, clinical outcomes, and biomarker profiles were extracted, and due to study heterogeneity, a narrative synthesis was performed, without risk-of-bias assessment or meta-analysis. Results: Twenty-five studies were included, with 3298 patients enrolled overall. Eighteen of these trials enrolled patients with advanced disease. All trials investigated ICI combination regimens, more frequently with chemotherapy, CDK4/6 inhibitors, or other immunotherapeutic agents. Most of the studies enrolling patients with advanced disease failed to show a significant clinical activity of ICIs. In the early setting, neoadjuvant chemo-immunotherapy with nivolumab or pembrolizumab increased the rate of complete responses compared to chemotherapy alone. Moreover, high programmed death-ligand 1 (PD-L1) expression, low ER (estrogen receptor), and high tumor-infiltrating lymphocyte (TIL) levels correlated with improved outcomes. Consistently, markers indicating enhanced immune activation, such as the MammaPrint High 2 (MP2) genomic signature, were associated with increased ICI sensitivity. Discussion: Despite the limited overall efficacy, ICIs may represent a viable therapeutic option for a selected subset of HR+/HER2− BC patients. However, this systematic review is limited by study heterogeneity and the inclusion of ongoing or immature trials, which prevents quantitative analysis and may affect future conclusions on ICIs in HR+/HER2− breast cancer. Finally, optimized combination strategies could enhance tumor immunogenicity, while predictive biomarkers such as PD-L1, TILs, or specific genomic signatures could identify responsive patients.

4 July 2025 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
Giuseppe Di GraziaGiuseppe Di Grazia
Giuseppe Di Grazia
CCChiara Conti
Chiara Conti
SNSabrina Nucera
Sabrina Nucera
SSStefania Stella
Stefania Stella
MMMichele Massimino
Michele Massimino
FMFederica Martorana
Federica Martorana
Murine double minute 2 (MDM2) is a protein that plays a crucial role in the regulation of the tumor suppressor p53. It is involved in several biological processes and in cancer development, both in a p53-dependent and independent manner. Discordant evidence exists on MDM2 genetic polymorphisms and a possible susceptibility to breast cancer, but more studies are needed to fully understand this relationship. Elevated MDM2 levels, due to gene amplification or overexpression, can be found in up to 40 % of estrogen receptor positive breast cancers. These alterations exert antiapoptotic activity, promoting cell survival and resistance to treatment, through the degradation of p53. For this reason, evidence about MDM2 activity as an oncogene led to various approaches to counter its action in cancer. Several MDM2 inhibitors have been evaluated in in-vitro and in-vivo preclinical models, showing preliminary anticancer activity in various neoplasms, including breast cancer. Few of these agents have been tested in early phase clinical trials, alone or in combination, with some promising results, however showing significant drug toxicity. Wild type p53 may represent a potential biomarker of response. However, other biomarkers must be discovered to clearly select patients who can benefit from these therapies and new strategies are needed to manage their toxicity. In conclusion, further research is needed to fully understand the role of MDM2 in breast cancer and to develop targeted therapies that can effectively inhibit its function and at the same time limit the toxicity of so far experimented compounds.

22 October 2023 in Medicina
Verified
Journal Article
Open access
PDF file
FMFederica Martorana
Federica Martorana
Giuseppe Di GraziaGiuseppe Di Grazia
Giuseppe Di Grazia
GRGiovanni Rosano
Giovanni Rosano
GVGiada Maria Vecchio
Giada Maria Vecchio
CCChiara Conti
Chiara Conti
PVPaolo VIGNERI
Paolo VIGNERI
Triple-negative breast cancer (TNBC) represents about 15% of all breast cancers and is usually characterized by aggressive clinical behavior and a poor prognosis. Four TNBC subgroups have been previously defined with different molecular profiles: (i) luminal androgen receptor (LAR), (ii) mesenchymal (MES), (iii) basal-like immunosuppressed (BLIS) and (iv) basal-like immune-activated (BLIA). Among these, LAR is characterized by the expression of the androgen receptor (AR), and exhibits genomic characteristics that resemble luminal breast cancers, with a still undefined prognosis and clinical behavior. Here, we report a case of a woman affected by recurring LAR TNBC, which underwent phenotypic changes throughout its natural history. After the initial diagnosis of LAR breast cancer, the patient experienced local recurrence with strong expression of the estrogen receptor. Due to this finding, she started treatment with a CDK4/6-inhibitor and an aromatase inhibitor, followed by oral vinorelbine, both with dismal outcomes. Then, she received everolimus and exemestane, which determined temporary disease stabilization. An extensive NGS analysis of tumor tissue showed PIK3CA and HER2 mutations. Our case is consistent with previous reports of LAR breast cancer and underlines the potential utility of re-biopsy and molecular testing in breast cancer (BC), especially in rare subtypes.

1 August 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Giuseppe Di GraziaGiuseppe Di Grazia
Giuseppe Di Grazia
CCChiara Conti
Chiara Conti
SNSabrina Nucera
Sabrina Nucera
GMGianmarco Motta
Gianmarco Motta
FMFederica Martorana
Federica Martorana
PVPaolo Vigneri
Paolo Vigneri
The REarranged during Transfection (RET) receptor tyrosine kinase plays a crucial role in the development of various anatomical structures during embryogenesis and it is involved in many physiological cellular processes. This protein is also associated with the initiation of various cancer types, such as thyroid cancer, non-small cell lung cancer, and multiple endocrine neoplasms. In breast cancer, and especially in the estrogen receptor-positive (ER+) subtype, the activity of RET is of notable importance. Indeed, RET seems to be involved in tumor progression, resistance to therapies, and cellular proliferation. Nevertheless, the ways RET alterations could impact the prognosis of breast cancer and its response to treatment remain only partially elucidated. Several inhibitors of RET kinase have been developed thus far, with various degrees of selectivity toward RET inhibition. These molecules showed notable efficacy in the treatment of RET-driven tumors, including some breast cancer cases. Despite these encouraging results, further investigation is needed to fully understand the potential role RET inhibition in breast cancer. This review aims to recapitulate the existing evidence about the role of RET oncogene in breast cancer, from its pathogenic and potentially prognostic role, to the clinical applications of RET inhibitors.

12 August 2025 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
Francesco SchettiniFrancesco Schettini
Francesco Schettini
SNSabrina Nucera
Sabrina Nucera
Giuseppe Di GraziaGiuseppe Di Grazia
Giuseppe Di Grazia
FGFabiola Giudici
Fabiola Giudici
CSCarla Strina
Carla Strina
Daniele GeneraliDaniele Generali
Daniele Generali
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are the standard-of-care for hormone receptor-positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC). Palbociclib, the first approved CDK4/6i, significantly improved progression-free survival (PFS) in randomized controlled trials (RCTs). However, real-world (RW) outcomes may differ due to broader patient populations. This meta-analysis evaluates the applicability of pivotal RCT findings to RW settings. Methods: We conducted a systematic review and meta-analysis of RW studies on HR+/HER2− MBC treated with palbociclib+aromatase inhibitors (AI) or fulvestrant, reporting median PFS (mPFS) and/or overall survival (mOS). Pooled mPFS/OS was estimated using the median of medians (MM) and weighted MM (WM). RW estimates were deemed comparable to RCTs if MMPFS/OS or WMPFS/OS fell within RCTs’ 95% confidence intervals (CI). Similar criteria applied to pooled hazard ratios (HR) of PFS/OS for palbociclib+AI vs AI in visceral/non-visceral subgroups. Results: Twelve RW studies were analyzed. First-line palbociclib+AI MMPFS (22.5 months, 95%CI: 19.5–31.8) aligned with PALOMA-1/2 pooled mPFS (23.9, 95% CI: 20.2–27.6). First-line palbociclib+fulvestrant MMPFS (13.5, 95%CI: 11.6–28.5) exceeded PALOMA-3 (11.2, 95%CI: 9.5–12.9). Second-line palbociclib+fulvestrant MMPFS (11.5 months, 95%CI: 6.3–15.3) was consistent with PALOMA-3. RW first-line mOS (51.2 months, 95%CI: 49.1–53.3) surpassed PALOMA-1/2 pooled mOS (45.7, 95%CI: 37.5–53.8). WMOS (49.1 months, 95%CI: 49.1–53.3) was slightly lower than RCTs (53.7, 95%CI: 37.5–53.8). Palbociclib+AI outperformed AI in RW visceral disease, aligning with RCTs, and showed heterogeneous but favorable benefit in non-visceral disease. Conclusions: RW data confirm palbociclib+endocrine therapy effectiveness, reinforcing its applicability to broader patient populations.

22 May 2026 in European Journal of Cancer
Verified
Journal Article
Open access
Giuseppe Di GraziaGiuseppe Di Grazia
Giuseppe Di Grazia
VLVincenzo Di Lauro
Vincenzo Di Lauro
DMDaniel Morchón
Daniel Morchón
SNSabrina Nucera
Sabrina Nucera
LFLuis Figuero-Pérez
Luis Figuero-Pérez
Francesco SchettiniFrancesco Schettini
Francesco Schettini
Genomic assays (GA) guide chemotherapy (CT) use in stage I-II endocrine receptor-positive (ER+)/HER2-negative (HER2-) breast cancer (BC). In tumors N0/intermediate-risk or N1/low-to-intermediate-risk, randomized trials with OncotypeDX® showed a CT benefit only for women aged≤ 50 years/premenopausal. Comparable data for the Prosigna® GA are lacking. We retrospectively included 567 women aged≤ 50 years with stage I-II ER+ /HER2 - BC tested with Prosigna® across 10 hospitals in Spain/Italy (2014-2023). Patients received endocrine therapy (ET) with/without (neo)adjuvant CT. Event-free survival (EFS) was analyzed using Kaplan-Meier curves, log-rank tests, and Cox regression. Propensity score matching (PSM) was applied. 5-year EFS rates were numerically compared with those of OncotypeDX® trials. Of 567 patients, 73.7% were N0 and 26.3% N1, 39.7% were Prosigna risk-of-relapse (ROR)-low (RL), 33.0% ROR-intermediate (RI), 27.3% ROR-high (RH) and 48.3% received CT. CT independently improved EFS in N0/RI and N1/RL-RI (5-year EFS 97.9% vs. 86.6%; adjusted hazard ratio=0.07, p = 0.018). In premenopausal women, CT benefit persisted only when adjuvant gonadotropin-releasing hormone analogue was not administered (p = 0.008), especially in N0/RI (p = 0.023). Results were confirmed after PSM. CT-treated N0/RH showed similar EFS to CT-treated N0/RI+N1/RL-RI, while N1/RH showed poor prognosis despite CT use. 5-year EFS rates were generally consistent with OncotypeDX® trials. Prosigna can help identify young women with stage I-II ER+ /HER2- BC who gain benefit from (neo)adjuvant CT and those in need of further escalated treatments. In premenopausal N0/RI and N1/RL-RI disease, the effect of CT seems to be driven by ovarian function suppression. Prospective validation is required.